Inhibiting the oncogene c-Myc and mutant KRas remains a major challenge in cancer research. c-Myc and KRas are hyperactive in more than 70% of all human cancers, and contribute to resistance to therapies. However, drugs that directly inhibit c-Myc or mutant KRas have not yet been developed. c- Myc and KRas are key oncogenic drivers in colorectal cancer, a leading cause of cancer death; nearly 100% of colorectal cancers depend on c-Myc, while KRas mutations occur in ~50% of colorectal cancers. Recent findings indicate that post-translational modification by the Small Ubiquitin-like MOdifiers (SUMO) play a critical role in c-Myc and KRas-dependent oncogenesis; however, the mechanisms of how SUMOylaton is involved in c-Myc and KRas-dependent oncogenesis are not well understood. Wnt-signaling pathways could be a critical link of SUMOylation to both c-Myc activation and KRas mutation in colorectal cancers. Dysregulated Wnt-signaling leads to increased c-Myc expression and activity. In addition, KRas mutation suppresses the non-canonical Wnt signaling pathway, thereby enhancing the canonical Wnt-signaling pathway. Wnt signaling is also key to maintaining the pool of cancer stem cells in a wide range of cancers. During the previous funding period, we found that inhibition of SUMOylation significantly suppressed Wnt down-stream targets, including c-Myc. Key proteins, both in the canonical and non-canonical Wnt pathways, have been recently shown to be substrates of SUMOylation. However, the current understanding of how SUMOylation regulates the Wnt pathways is incomplete, and thus will be investigated here using colorectal cancer as a model system. We will conduct a combination of structural studies and chemical synthesis to determine the mechanism of allosteric inhibition by our lead small molecule SUMOylation inhibitor. We will conduct biochemical and molecular biological studies to elucidate the mechanism of SUMOylation in the Wnt signaling pathways. Finally, we will determine the therapeutic efficacy of our lead SUMOylation small molecule inhibitor in c-Myc and KRas-dependent colorectal cancers. We expect that the proposed studies will lead to a new paradigm by providing proof of principle for much-needed therapies that target c-Myc and KRas and dysregulated Wnt-signaling. Our work will also have implications for the many other cancers that are dependent on c-Myc and KRas. !

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM086171-11
Application #
9647470
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Janes, Daniel E
Project Start
2008-04-01
Project End
2021-01-31
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
11
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Jiang, Xi; Hu, Chao; Ferchen, Kyle et al. (2018) Author Correction: Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Nat Commun 9:670
Ambaye, Nigus; Chen, Chih-Hong; Khanna, Swati et al. (2018) Streptonigrin Inhibits SENP1 and Reduces the Protein Level of Hypoxia-Inducible Factor 1? (HIF1?) in Cells. Biochemistry 57:1807-1813
Yan, Wei; Wu, Xiwei; Zhou, Weiying et al. (2018) Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol 20:597-609
Lv, Zongyang; Yuan, Lingmin; Atkison, James H et al. (2018) Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme. Nat Commun 9:5145
Lv, Zongyang; Yuan, Lingmin; Atkison, James H et al. (2017) Domain alternation and active site remodeling are conserved structural features of ubiquitin E1. J Biol Chem 292:12089-12099
Cho, May; Gong, Jun; Frankel, Paul et al. (2017) A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy. Oncotarget 8:79750-79760
Yue, Peibin; Lopez-Tapia, Francisco; Paladino, David et al. (2016) Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes In Vitro and In Vivo. Cancer Res 76:652-63
Alontaga, Aileen Y; Ambaye, Nigus D; Li, Yi-Jia et al. (2016) Observation of an E2 (Ubc9)-homodimer by crystallography. Data Brief 7:195-200
Namanja, Andrew T; Wang, Jianghai; Buettner, Ralf et al. (2016) Allosteric Communication across STAT3 Domains Associated with STAT3 Function and Disease-Causing Mutation. J Mol Biol 428:579-589
Kuo, Ching-Ying; Cheng, Chun-Ting; Hou, Peifeng et al. (2016) HIF-1-alpha links mitochondrial perturbation to the dynamic acquisition of breast cancer tumorigenicity. Oncotarget 7:34052-69

Showing the most recent 10 out of 40 publications